单细胞研究指南:测序方法大比拼

2016-05-18 佚名 Ebiotrade

多细胞生物的每个细胞都携带着相同的遗传学信息。不过,近年来蓬勃发展的单细胞研究告诉我们,每一个细胞都是独一无二的。The Scientist杂志最近联系了单细胞研究领域的一些专家,请他们分享了在单细胞中进行转录研究的秘诀。希望帮助研究者们更好地构建文库,处理和分析结果数据。那么,细胞之间的哪些差异有生物学意义,哪些差异来自于技术偏好呢?要获得可靠的结果又需要研究多少细胞呢?这些问题曾经是单细胞

多细胞生物的每个细胞都携带着相同的遗传学信息。不过,近年来蓬勃发展的单细胞研究告诉我们,每一个细胞都是独一无二的。The Scientist杂志最近联系了单细胞研究领域的一些专家,请他们分享了在单细胞中进行转录研究的秘诀。希望帮助研究者们更好地构建文库,处理和分析结果数据。

那么,细胞之间的哪些差异有生物学意义,哪些差异来自于技术偏好呢?要获得可靠的结果又需要研究多少细胞呢?这些问题曾经是单细胞研究(尤其是单细胞转录组研究)的拦路虎,令人望而却步。单细胞RNA测序(scRNA-seq)和单细胞数据分析工具在这方面为人们提供了很大的帮助。

The Scientist杂志最近联系了单细胞研究领域的一些专家,请他们分享了在单细胞中进行转录研究的秘诀。希望帮助研究者们更好地构建文库,处理和分析结果数据。

测序方法大比拼

在单细胞研究的大潮中,新的测序方法层出不穷。不过,很少有人对这些方法进行系统的比对。慕尼黑大学生物学家Wolfgang Enard最近领导团队,在小鼠胚胎干细胞的基因表达研究中比较了一些常用的单细胞测序方法,包括Smart-seq、CEL-seq、SCRB-seq和Drop-seq。

Smart-seq

SMART(Switching mechanism at 5’ end of the RNA transcript)是一个具有里程碑意义的重要技术。实际上,能够从单细胞生成全长cDNA的测序方案并不多,Smartseq就是其中之一。对于等位基因特异性表达或者剪接变体研究来说,覆盖整个转录组是一件非常重要的事情。

Fluidigm C1单细胞制备系统能够自动完成Smart-seq步骤。你只需要将制备好的细胞悬液加进去,仪器就会分离并裂解细胞,把mRNA逆转录为cDNA,再对cDNA进行扩增。扩增后的cDNA可以拿来测序,也可以进行qPCR检测。

在Enard的比较研究中,Fluidigm C1系统的Smart-seq最为灵敏,成本也最高。这一系统使用的微流体芯片不能重复使用,不过这种芯片可以放到显微镜下观察,证实健康单细胞的存在。

斯坦福大学的著名学者Stephen Quake及其团队利用Fluidigm C1单细胞制备系统,对人类大脑皮层的482个单细胞进行了高通量转录组测序,最终得到了466个单细胞的RNA测序数据。数据分析表明,单细胞测序结果不但能用于区分神经元、神经胶质细胞以及血管细胞,还能将神经元分为五类兴奋性细胞和两类抑制性细胞。

CEL-seq

CEL-seq(Cell expression by linear amplification and sequencing)是一种采用线性扩增的常用测序方法。线性扩增的主要优势是错误率比较低,不过线性扩增和PCR都存在序列依赖性偏好。

CEL-seq技术发表于2012年,主要是分离单细胞,逆转录带有poly-A 尾巴的mRNA片段,给它们贴上代表其细胞来源的条码。2014年Science杂志发布的MARS-seq与CEL-seq很类似。

CEL-seq和其他线性扩增方法生成文库花费的时间要稍微长一点。不过,CEL-seq在早期阶段就给样本贴上条码并进行混合,大大减少了手动操作的时间。PCR是在最后阶段使用的,主要是为了连接正确的测序接头,CEL-seq开发者纽约大学的Itai Yanai介绍到。

CEL-seq所需试剂都是现成的,大约两天时间生成测序文库和测序数据,Yanai指出。需要注意的是,CEL-seq与大多数方案一样,测序转录本的3’ 端。Enard等人并没有亲自尝试着一技术,只是在比较研究中用到了CEL-seq数据。从这项研究来看,CEL-seq的重现性最好。GitHub网站提供有CEL-seq可用的生物信息学工具。Yanai研究团队正在开发新版本CELseq2,新版本的灵敏度将比旧版本高三倍。

SCRB-seq

Broad研究所开发的SCRB-seq(single-cell RNA barcoding and sequencing)技术采用的是PCR扩增。该技术需要结合流式细胞仪(FACS)或者其他细胞分选方法,把单细胞分配到微孔里去。

SCRB-seq与Smart-seq比较相似,只不过SCRB-seq会整合特异性的细胞条码,以分辨扩增分子的来源,更准确的定量转录本。此外,SCRB-seq并不生成全长cDNA,而是像CELseq一样富集RNA3’端。

2014年,开发者们将SCRB-seq技术提前发布在BioRXiv上。随后他们对这一技术进行了更新,并将其更名为“high-throughput eukaryote 3’ digital gene expression”。Broad研究所仍提供有SCRB-seq技术服务,SCRB-seq也被整合到了WaferGen Biosystems公司的scRNA-seq平台上。

据说Fluidigm公司的C1系统很快也将支持SCRB-seq方案。SCRB-seq目前是Enard最中意的测序方法,它不仅适用于单细胞RNA测序,还能支持大量细胞(bulk)的RNA测序。可惜的是SCRB-seq并不好DIY,研究者自己很难将测序流程与FACS对接起来。

目前,在单细胞中揭示DNA甲基化与基因表达的直接关联还比较困难。这是因为细胞之间存在较大的差异,又不能同时检测一个细胞的转录组和甲基化组。加州大学范国平教授和同济大学薛志刚教授在5月5日的Genome Biology杂志上发布了自己开发的新测序方法——scMT-seq。这种方法能够同时分析单个细胞的转录组和甲基化组。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=105797, encodeId=fc63105e9745, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:47:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105596, encodeId=dbe21055963d, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:26:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86723, encodeId=4b3586e2333, content=只能说,发展太快了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/21b1fa92cec74fb5b0b160bcc3a13716/3df82edb6cc74c2a9a5a9b5faef160f1.jpg, createdBy=40c81607191, createdName=shanganquan, createdTime=Sat May 21 07:17:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86558, encodeId=c50b8655831, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:41:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86557, encodeId=ffc98655e9a, content=基础文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:40:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86261, encodeId=e4c6862612a, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 18 15:01:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-08-27 李东泽

    这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=105797, encodeId=fc63105e9745, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:47:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105596, encodeId=dbe21055963d, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:26:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86723, encodeId=4b3586e2333, content=只能说,发展太快了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/21b1fa92cec74fb5b0b160bcc3a13716/3df82edb6cc74c2a9a5a9b5faef160f1.jpg, createdBy=40c81607191, createdName=shanganquan, createdTime=Sat May 21 07:17:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86558, encodeId=c50b8655831, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:41:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86557, encodeId=ffc98655e9a, content=基础文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:40:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86261, encodeId=e4c6862612a, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 18 15:01:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-08-27 李东泽

    这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=105797, encodeId=fc63105e9745, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:47:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105596, encodeId=dbe21055963d, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:26:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86723, encodeId=4b3586e2333, content=只能说,发展太快了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/21b1fa92cec74fb5b0b160bcc3a13716/3df82edb6cc74c2a9a5a9b5faef160f1.jpg, createdBy=40c81607191, createdName=shanganquan, createdTime=Sat May 21 07:17:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86558, encodeId=c50b8655831, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:41:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86557, encodeId=ffc98655e9a, content=基础文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:40:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86261, encodeId=e4c6862612a, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 18 15:01:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-21 shanganquan

    只能说,发展太快了!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=105797, encodeId=fc63105e9745, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:47:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105596, encodeId=dbe21055963d, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:26:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86723, encodeId=4b3586e2333, content=只能说,发展太快了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/21b1fa92cec74fb5b0b160bcc3a13716/3df82edb6cc74c2a9a5a9b5faef160f1.jpg, createdBy=40c81607191, createdName=shanganquan, createdTime=Sat May 21 07:17:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86558, encodeId=c50b8655831, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:41:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86557, encodeId=ffc98655e9a, content=基础文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:40:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86261, encodeId=e4c6862612a, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 18 15:01:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-19 milkshark

    值得学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=105797, encodeId=fc63105e9745, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:47:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105596, encodeId=dbe21055963d, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:26:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86723, encodeId=4b3586e2333, content=只能说,发展太快了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/21b1fa92cec74fb5b0b160bcc3a13716/3df82edb6cc74c2a9a5a9b5faef160f1.jpg, createdBy=40c81607191, createdName=shanganquan, createdTime=Sat May 21 07:17:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86558, encodeId=c50b8655831, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:41:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86557, encodeId=ffc98655e9a, content=基础文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:40:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86261, encodeId=e4c6862612a, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 18 15:01:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-19 milkshark

    基础文章

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=105797, encodeId=fc63105e9745, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:47:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105596, encodeId=dbe21055963d, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:26:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86723, encodeId=4b3586e2333, content=只能说,发展太快了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/21b1fa92cec74fb5b0b160bcc3a13716/3df82edb6cc74c2a9a5a9b5faef160f1.jpg, createdBy=40c81607191, createdName=shanganquan, createdTime=Sat May 21 07:17:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86558, encodeId=c50b8655831, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:41:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86557, encodeId=ffc98655e9a, content=基础文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:40:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86261, encodeId=e4c6862612a, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 18 15:01:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-18 1dd8c52fm63(暂无匿称)

    了解一下!

    0

相关资讯

NIH悬赏10万美元,寻求单细胞分析解决方案

细胞是生物体结构和生命活动的基本单元。在单个细胞水平上进行研究,可以获得反映细胞生理状态和过程的更准确、更全面的信息,还可以使人们能更好地了解细胞群体中某些特殊的细胞功能,更深入地认识细胞个体差异、细胞间相互作用和信息传递以及神经递质、药物或毒物刺激的生理影响等更深层次的信息。因此,单细胞分析技术的研究与发展具有重要意义,已成为分析科学中的一个新兴的前沿领域。NIH悬赏10万美元,寻求单细胞分

Nature:新型单细胞分析技术揭示干细胞中的复杂突变

近日,来自波士顿儿童医院等处的研究人员利用新型的单细胞基因分析技术揭示了多能干细胞的多种遗传突变,相关研究刊登于国际著名杂志Nature上,为后期开发治疗疾病的新型再生性疗法提供了一定的帮助和希望。 研究者James Collins表示,在单一细胞之间干细胞群体会包含许多差异,而这在干细胞工程学领域开发预测性的方法却会带来一点问题,如今研究者发现,他们此前考虑过的细胞间的问题性差异或许实际上

Cell:单细胞全基因组高精彩度测序技术

日前,《细胞》(Cell)杂志上分别报道了来自中国学者的两项最新研究成果。复旦大学的徐彦辉等人首次破解 TET2 -DNA复合物的晶体结构;而来自北京大学的乔杰、汤富酬和谢晓亮等人则发布了突破性单细胞基因组检测技术。  徐彦辉 在第一篇文章中,研究人员首次成功解析了哺乳动物(mammal;mammalian)骨髓造血关键蛋白 TET2 的三维结构。该成果对揭示疾病发病